Advanced Enzyme Technologies Limited Total Liabilities
Advanced Enzyme Technologies Limited total liabilities. Based on the latest financial reports, Advanced Enzyme Technologies Limited (ADVENZYMES) has total liabilities worth Rs-16.83 Billion INR (≈ $-182.02 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ADVENZYMES asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Advanced Enzyme Technologies Limited (2008–2026)
Total liabilities of Advanced Enzyme Technologies Limited from 2008 to 2026. This chart illustrates how Advanced Enzyme Technologies Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Advanced Enzyme Technologies Limited long-term investment intensity to see how much of total assets are deployed in long-term investments.
Advanced Enzyme Technologies Limited Competitors by Total Liabilities
The table below lists competitors of Advanced Enzyme Technologies Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Goody Science & Technology Co Ltd
SHE:002694
|
China | CN¥1.12 Billion |
|
Immobiliere Dassault SA
PA:IMDA
|
France | €487.75 Million |
|
Ace Hardware Indonesia Tbk
JK:ACES
|
Indonesia | Rp2.28 Trillion |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$34.26 Million |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
India | Rs-37.83 Billion |
|
Zhejiang Tailin Bioengineering Co Ltd
SHE:300813
|
China | CN¥140.46 Million |
|
Hangzhou Prevail Optoelectronic Equipment Co Ltd
SHE:300710
|
China | CN¥101.07 Million |
|
Mobia Medical, Inc. Common Stock
NASDAQ:MOBI
|
USA | $22.68 Million |
Liability Composition Analysis (2008–2026)
This chart breaks down Advanced Enzyme Technologies Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ADVENZYMES total assets.
Liquidity & Leverage Metrics
Advanced Enzyme Technologies Limited Total Liabilities Ratios Explained
Advanced Enzyme Technologies Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advanced Enzyme Technologies Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advanced Enzyme Technologies Limited (2008–2026)
The table below shows the annual total liabilities of Advanced Enzyme Technologies Limited from 2008 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs1.56 Billion ≈ $16.83 Million |
+1.94% |
| 2025-03-31 | Rs1.53 Billion ≈ $16.51 Million |
-7.12% |
| 2024-03-31 | Rs1.64 Billion ≈ $17.78 Million |
+19.40% |
| 2023-03-31 | Rs1.38 Billion ≈ $14.89 Million |
+8.22% |
| 2022-03-31 | Rs1.27 Billion ≈ $13.76 Million |
+4.36% |
| 2021-03-31 | Rs1.22 Billion ≈ $13.18 Million |
+9.67% |
| 2020-03-31 | Rs1.11 Billion ≈ $12.02 Million |
+4.58% |
| 2019-03-31 | Rs1.06 Billion ≈ $11.49 Million |
-29.13% |
| 2018-03-31 | Rs1.50 Billion ≈ $16.22 Million |
+44.13% |
| 2017-03-31 | Rs1.04 Billion ≈ $11.25 Million |
-37.73% |
| 2016-03-31 | Rs1.67 Billion ≈ $18.07 Million |
-16.24% |
| 2015-03-31 | Rs1.99 Billion ≈ $21.57 Million |
-15.12% |
| 2014-03-31 | Rs2.35 Billion ≈ $25.42 Million |
+2.14% |
| 2013-03-31 | Rs2.30 Billion ≈ $24.88 Million |
-8.30% |
| 2012-03-31 | Rs2.51 Billion ≈ $27.14 Million |
+180.57% |
| 2011-03-31 | Rs894.39 Million ≈ $9.67 Million |
+48.72% |
| 2010-03-31 | Rs601.38 Million ≈ $6.50 Million |
+7.27% |
| 2009-03-31 | Rs560.60 Million ≈ $6.06 Million |
-4.56% |
| 2008-03-31 | Rs587.36 Million ≈ $6.35 Million |
-- |
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain… Read more